- Home
- AVT vs AKRO Comparison
AVT vs AKRO Comparison
Compare AVT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVT
- AKRO
- Stock Information
- Founded
- AVT 1921
- AKRO 2017
- Country
- AVT United States
- AKRO United States
- Employees
- AVT N/A
- AKRO N/A
- Industry
- AVT Electronic Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- AVT Technology
- AKRO Health Care
- Exchange
- AVT Nasdaq
- AKRO Nasdaq
- Market Cap
- AVT 4.4B
- AKRO 3.9B
- IPO Year
- AVT N/A
- AKRO 2019
- Fundamental
- Price
- AVT $50.01
- AKRO $49.65
- Analyst Decision
- AVT Sell
- AKRO Strong Buy
- Analyst Count
- AVT 4
- AKRO 8
- Target Price
- AVT $49.00
- AKRO $82.50
- AVG Volume (30 Days)
- AVT 644.3K
- AKRO 1.9M
- Earning Date
- AVT 04-30-2025
- AKRO 05-12-2025
- Dividend Yield
- AVT 2.64%
- AKRO N/A
- EPS Growth
- AVT N/A
- AKRO N/A
- EPS
- AVT 3.56
- AKRO N/A
- Revenue
- AVT $22,145,935,000.00
- AKRO N/A
- Revenue This Year
- AVT N/A
- AKRO N/A
- Revenue Next Year
- AVT $3.46
- AKRO N/A
- P/E Ratio
- AVT $14.06
- AKRO N/A
- Revenue Growth
- AVT N/A
- AKRO N/A
- 52 Week Low
- AVT $39.22
- AKRO $17.86
- 52 Week High
- AVT $59.24
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- AVT 49.51
- AKRO 63.34
- Support Level
- AVT $49.13
- AKRO $44.94
- Resistance Level
- AVT $51.09
- AKRO $49.29
- Average True Range (ATR)
- AVT 0.89
- AKRO 3.33
- MACD
- AVT -0.21
- AKRO 0.67
- Stochastic Oscillator
- AVT 22.98
- AKRO 86.02
About AVT Avnet Inc.
Avnet Inc is a global distributor of electronic components, connecting suppliers of semiconductors and other components to a base of 2.1 million small- and mid-sized customers in 140 countries. Avnet is the third largest semiconductor distributor in the world, and the largest for European chip distribution. Avnet services all levels of electronics design and development, servicing engineers with design tools, test kits, and services alongside its high-volume distribution for final designs.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.